Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile.

Chiara Saponaro(University of Pisa), Amalia Gastaldelli(National Research Council), L. Mezzabotta(University of Turin), Antonina Smedile(Ospedale Papa Giovanni XXIII), Demetrio Ciociaro, Maria Lorena Abate(University of Turin), Roberto Gambino(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Elisabetta Bugianesi(University of Turin), Riccardo Faletti(University of Turin), Maurizio Cassader(University of Turin), Mario Rizzetto(University of Turin), Federica Carli, Francesca Saba(University of Turin), E. Buzzigoli(Istituto di Fisiologia Clinica), Chiara Rosso(University of Turin), Andrea Marengo(University of Turin), Melania Gaggini(Istituto di Fisiologia Clinica)
CINECA IRIS Institutial research information system (University of Pisa)
January 1, 2015
Cited by 0

Related Papers

A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
|Hepatology|2003|2.7k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k